Inari Medical, Inc. (NASDAQ:NARI) Director Sells $43,755.96 in Stock

Inari Medical, Inc. (NASDAQ:NARI) Director Rebecca Chambers sold 964 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was sold at an average price of $45.39, for a total value of $43,755.96. Following the sale, the director now directly owns 9,944 shares of the company’s stock, valued at approximately $451,358.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Inari Medical Price Performance

NARI opened at $45.72 on Wednesday. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $71.85. The business has a fifty day moving average price of $42.57 and a 200 day moving average price of $52.63.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.15). The business had revenue of $143.19 million for the quarter, compared to analysts’ expectations of $138.32 million. Inari Medical had a negative return on equity of 1.65% and a negative net margin of 4.54%. Research analysts anticipate that Inari Medical, Inc. will post -0.41 EPS for the current year.

Hedge Funds Weigh In On Inari Medical

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Inari Medical by 11.1% in the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after acquiring an additional 561,562 shares during the period. Brown Advisory Inc. increased its position in Inari Medical by 17.6% in the 4th quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company’s stock valued at $110,501,000 after acquiring an additional 255,182 shares during the period. Bamco Inc. NY increased its position in Inari Medical by 27.4% during the 1st quarter. Bamco Inc. NY now owns 777,152 shares of the company’s stock worth $37,288,000 after purchasing an additional 167,000 shares during the period. Dimensional Fund Advisors LP increased its position in Inari Medical by 7.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock worth $38,693,000 after purchasing an additional 41,555 shares during the period. Finally, Principal Financial Group Inc. increased its position in Inari Medical by 23.4% during the 4th quarter. Principal Financial Group Inc. now owns 567,266 shares of the company’s stock worth $36,827,000 after purchasing an additional 107,622 shares during the period. Institutional investors and hedge funds own 90.98% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on NARI. Needham & Company LLC cut their target price on Inari Medical from $72.00 to $57.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Canaccord Genuity Group cut their target price on Inari Medical from $75.00 to $55.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. Truist Financial dropped their price objective on Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research note on Friday, March 22nd. Piper Sandler dropped their price objective on Inari Medical from $55.00 to $50.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. Finally, Wells Fargo & Company dropped their price objective on Inari Medical from $100.00 to $84.00 and set an “overweight” rating for the company in a research note on Wednesday, May 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $65.71.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.